These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 23045428)

  • 21. The Aldosterone Synthase Inhibitor FAD286 is Suitable for Lowering Aldosterone Levels in ZDF Rats but not in db/db Mice.
    Hofmann A; Brunssen C; Peitzsch M; Balyura M; Mittag J; Frenzel A; Jannasch A; Brown NF; Weldon SM; Gueneva-Boucheva KK; Eisenhofer G; Bornstein SR; Morawietz H
    Horm Metab Res; 2017 Jun; 49(6):466-471. PubMed ID: 28427090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of variation in CYP11B1 and CYP11B2 on corticosteroid phenotype and hypothalamic-pituitary-adrenal axis activity in hypertensive and normotensive subjects.
    Freel EM; Ingram M; Wallace AM; White A; Fraser R; Davies E; Connell JM
    Clin Endocrinol (Oxf); 2008 May; 68(5):700-6. PubMed ID: 17980006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A steady state system for in vitro evaluation of steroidogenic pathway dynamics: Application for CYP11B1, CYP11B2 and CYP17 inhibitors.
    Mangelis A; Jühlen R; Dieterich P; Peitzsch M; Lenders JWM; Hahner S; Schirbel A; Eisenhofer G
    J Steroid Biochem Mol Biol; 2019 Apr; 188():38-47. PubMed ID: 30529282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11beta-hydroxylase) inhibitors.
    Müller-Vieira U; Angotti M; Hartmann RW
    J Steroid Biochem Mol Biol; 2005 Aug; 96(3-4):259-70. PubMed ID: 15985365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heteroatom insertion into 3,4-dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase.
    Grombein CM; Hu Q; Rau S; Zimmer C; Hartmann RW
    Eur J Med Chem; 2015 Jan; 90():788-96. PubMed ID: 25528333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disorders of the aldosterone synthase and steroid 11beta-hydroxylase deficiencies.
    Peter M; Dubuis JM; Sippell WG
    Horm Res; 1999; 51(5):211-22. PubMed ID: 10559665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of polymorphisms in the gene encoding aldosterone synthase (CYP11B2) on steroid synthesis and blood pressure regulation.
    Connell JM; Fraser R; MacKenzie SM; Friel EC; Ingram MC; Holloway CD; Davies E
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):243-7. PubMed ID: 15134824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Aldosterone Synthase Inhibitor FAD286 on Steroid Hormone Profile in Human Adrenocortical Cells.
    Brunssen C; Hofmann A; Peitzsch M; Frenzel A; Ziegler CG; Brown NF; Weldon SM; Eisenhofer G; Willenberg HS; Bornstein SR; Morawietz H
    Horm Metab Res; 2017 Sep; 49(9):701-706. PubMed ID: 28759940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase.
    Sloan-Lancaster J; Raddad E; Flynt A; Jin Y; Voelker J; Miller JW
    J Renin Angiotensin Aldosterone Syst; 2017; 18(3):1470320317717883. PubMed ID: 28814143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural insights into aldosterone synthase substrate specificity and targeted inhibition.
    Strushkevich N; Gilep AA; Shen L; Arrowsmith CH; Edwards AM; Usanov SA; Park HW
    Mol Endocrinol; 2013 Feb; 27(2):315-24. PubMed ID: 23322723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.
    Santen RJ; Demers LM; Lynch J; Harvey H; Lipton A; Mulagha M; Hanagan J; Garber JE; Henderson IC; Navari RM
    J Clin Endocrinol Metab; 1991 Jul; 73(1):99-106. PubMed ID: 1646219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phenotypic consequences of variation across the aldosterone synthase and 11-beta hydroxylase locus in a hypertensive cohort: data from the MRC BRIGHT Study.
    Freel EM; Ingram M; Friel EC; Fraser R; Brown M; Samani NJ; Caulfield M; Munroe P; Farrall M; Webster J; Clayton D; Dominiczak AF; Davies E; Connell JM
    Clin Endocrinol (Oxf); 2007 Dec; 67(6):832-8. PubMed ID: 17651452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imidazopyridyl compounds as aldosterone synthase inhibitors.
    Whitehead BR; Lo MM; Ali A; Park MK; Hoyt SB; Xiong Y; Cai J; Carswell E; Cooke A; MacLean J; Ratcliffe P; Robinson J; Bennett DJ; Clemas JA; Wisniewski T; Struthers M; Cully D; MacNeil DJ
    Bioorg Med Chem Lett; 2017 Jan; 27(2):143-146. PubMed ID: 27979595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor.
    Shimizu H; Tortorici MA; Ohta Y; Ogawa K; Rahman SMA; Fujii A; Hiraga Y; Kawai M; Sugimoto-Kawabata K; van Iersel MT; van Lier JJ; Djedjos S; Slingsby BT; Rodman DM
    Clin Transl Sci; 2024 Aug; 17(8):e70000. PubMed ID: 39152532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.
    Adams CM; Hu CW; Jeng AY; Karki R; Ksander G; Lasala D; Leung-Chu J; Liang G; Liu Q; Meredith E; Rao C; Rigel DF; Shi J; Smith S; Springer C; Zhang C
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4324-7. PubMed ID: 20615692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacodynamic and pharmacokinetic characterization of the aldosterone synthase inhibitor FAD286 in two rodent models of hyperaldosteronism: comparison with the 11beta-hydroxylase inhibitor metyrapone.
    Rigel DF; Fu F; Beil M; Hu CW; Liang G; Jeng AY
    J Pharmacol Exp Ther; 2010 Jul; 334(1):232-43. PubMed ID: 20354176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of the fungicide epoxiconazole by virtual screening and biological assessment as inhibitor of human 11β-hydroxylase and aldosterone synthase.
    Akram M; Patt M; Kaserer T; Temml V; Waratchareeyakul W; Kratschmar DV; Haupenthal J; Hartmann RW; Odermatt A; Schuster D
    J Steroid Biochem Mol Biol; 2019 Sep; 192():105358. PubMed ID: 30965118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors.
    LaSala D; Shibanaka Y; Jeng AY
    Anal Biochem; 2009 Nov; 394(1):56-61. PubMed ID: 19622340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYP11B2 inhibitor dexfadrostat phosphate suppresses the aldosterone-to-renin ratio, an indicator of sodium retention, in healthy volunteers.
    Mulatero P; Groessl M; Vogt B; Schumacher C; Steele RE; Brooks A; Hossack S; Brunner HR
    Br J Clin Pharmacol; 2023 Aug; 89(8):2483-2496. PubMed ID: 36914591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase.
    Ulmschneider S; Müller-Vieira U; Mitrenga M; Hartmann RW; Oberwinkler-Marchais S; Klein CD; Bureik M; Bernhardt R; Antes I; Lengauer T
    J Med Chem; 2005 Mar; 48(6):1796-805. PubMed ID: 15771425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.